166: BioXcellerator - The Cutting Edge of Stem Cell Therapy

Longevity medicine is moving beyond symptom management—and regenerative therapies are forcing a deeper look at how healing actually works.

In this episode, Dr. Buck Joffrey speaks with the team at BioXcellerator about what separates rigorous regenerative medicine from hype-driven shortcuts.

The conversation focuses on why stem cells aren’t about “replacing” tissue, but about directing the body’s own repair systems through immune signaling, inflammation control, and cellular communication. Drawing from Buck’s own experience receiving treatment at BioXcellerator, the discussion unpacks why cell source, processing, viability, and delivery fundamentally shape outcomes.

They break down the differences between Wharton’s jelly–derived mesenchymal stem cells and adult autologous cells, how hypoxic culturing alters therapeutic signaling, and why exosomes alone are not interchangeable with living cells.

They also address the regulatory gray zones surrounding regenerative medicine and why high-quality real-world data matters in a field driven by complex biology.

Watch the full episode to understand how regenerative medicine actually works—and where it’s headed.

Learn more about BioXcellerator:

https://www.bioxcellerator.com/

Transcript

Disclaimer: This transcript was generated by AI and may not be 100% accurate. If you notice any errors or corrections, please email us at phil@longevityroadmap.com.

    The stem cells, they sense that microenvironment. And after sensing that microenvironment what they start producing as a cargo, it's being influenced by that microenvironment.

Welcome everybody. This is Longevity Roadmap with Buck Joffrey and today's show is sort of personal. Okay? Um, I'm gonna get into this stuff, uh, in the actual interviews, uh, part as well, but. Long story short, uh, back in January, so that was like 11 months ago, 10 months ago, whatever. Um, I had gone to Medellin Columbia to a place called Bioxcellerator for some injections,

uh,

of stem cell stem cell therapy, uh, into, uh, a couple of areas of chronic back pain.

And I was having a, you know, big flareups and stuff like that. So. I had a bunch of injections there. I had my hips. Um, I'm an ex hockey player. I had bilateral labral tears. You physicians out there know what that is. Just grinding constant pain, right? Low level grinding, constant pain, big nuisance. Anyway, I had sort of, uh, you know, and those hips, uh, I was thinking about all the time.

Pain's completely gone. It's pretty, it's pretty amazing actually. This is an, an area with stem cell therapy that I think a lot of people are kind of, they question it, they, they wonder if this is a real thing. And I think that's a reasonable question because, uh, there is a lot of fakery going on out there.

Right. Um, there is a, uh, gold rush towards regenerative medicine, uh, these days. And unfortunately in the US a lot of it is just kind of fake. It is fake. And so even some of the clinicians who are providing things, I, I mean, I think they even think that maybe there is some benefit in some of the things that they're doing, but there isn't that much because unfortunately in the US uh, there is, uh, too many regulations right now to, to really allow for.

Optimal use of, uh, this kind of technology stem cell technology. Um, but this, uh, interview, what we're doing is I'm gonna talk to the, uh, CEO, the founder of Bioxcellerator, along with the his Chief Medical Officer. And we're gonna dive into what exactly Bioxcellerator is. We're gonna talk about stem cells, how they work, which, you know, as a physician, you may not even know if you're a physician or a scientist or whatever.

You may not even know exactly what they're doing. They're not going and just, you know, turning into new organs, uh, or something like that. That's not what they do. We're gonna dive into the science and we're gonna talk about some of the limitations and broad applications as well. So, really interesting, uh, interview.

I think if you've got a problem, you know, that, uh, that you're thinking about, maybe surgery, whatever, I don't know, as a. Not only as a physician, but as somebody who has, uh, uh, experienced, uh, the benefit. I, I can't say I, I wouldn't give it a, potentially give it a try or at least think, think about it. Um, by the way, before I forget, um, if you are interested in a consultation with them, you know, certainly shoot me an email because they think I can get people discount.

Um. Shoot me an email buck@longevityroadmap.com. It's not a big discount. I think it's like 10% off or something. But um, yeah, if you're interested, do that and listen to this conversation. It is really fascinating and we will have that. To you right after these messages. Hey, longevity enthusiast. It's time to take it to the next level.

I've been fine tuning my longevity regimen for years, and I look better and feel better than I did a decade ago. In fact, my blood work is even better than it was back then, and it's all because of my data-driven regimen. And it's inspired me to create a course and community just for you. It's called the Longevity Roadmap, and I urge you to check it out.

If you're tired of your belly fat, tired of being tired, or just wanna optimize yourself for the next 50 years, visit longevity roadmap.com. That's longevity roadmap.com. Welcome back to Longevity Roadmap. Uh, today my guests are Eric Stoffers, founder and CEO of Bioxcellerator. Which is a regenerative medicine company focused on stem cell therapies for aging immune resilience and chronic disease.

He's got a background in private equity. Business development, and he's become a leading voice in translating emerging longevity science into real world applications. I've also got Dr. Karolynn Halpert, who's his employee number one and Chief Medical Officer, uh, at Bioxcellerator. Uh, she's a leader in regenerative medicine, former ER doc, uh, turned, uh, biotech innovator.

She sees, uh, she oversees the company's clinical and lab operations, uh, works to make advanced stem cell therapies, practical tools for extending health span and repairing tissue damage. Uh, welcome you two. It's, uh, great to have you.

Thank you. Thank you so much. Thank you. Thank you. Yeah. Yeah, it's always a pleasure to be here and, and, uh, get in front of your audience and talk about longevity.

So, Eric, you know, in the introduction, I talked a little bit about my experience and my experience as a summary was this. I went in there. Um, with, you know, a long, long history of back problems. I had a fusion, I've had discectomies. I, I've had all sorts of stuff. Um, and it was, uh, you know, I've been living with chronic back pain for a long time.

You know, I'm an ex hockey player and I have these, uh, uh, labral tears in my hips, both of them. And, uh, and basically for those people who don't know what that is, it's basically like a meniscus, sort of like, uh. Uh, if you think of knees, maybe you've heard of that, sort of the, just kind of a jelly material that, uh, that, that kind of keeps things kind of rotating.

Well, the hip joints are themselves are fine, but it was causing me, uh, a lot of pain. And, and in terms of the, the hips, I was told that well, or not a whole lot you can do because surgery itself at the, you do surgery on these, they don't, they're not great And, um, you know, you end up with. Situation where you're basically not able to walk, you know, they, they'd only even let you walk for several months.

And I was like, well anyway, so I go to Bioxcellerator and uh, and Eric's team over there. And, uh, I end up, uh, getting stem cell injections in Meine because it's not, you know, legal and approved in the US not knowing what really the outcome would be. Thinking, Hey, what do I got to lose? I can't do anything else with my hips.

And this was causing a serious issue for me. Like, I mean, I was in pain every day with my hips. Okay, so here's my experience, Eric, and I don't even know if you know this, but so the back, okay, my back has, uh, been stable. I haven't had any throw throwout situations since then. This was, this was January of this year.

Is now, uh, it is now November. So do I still have pain? Sure I do, and I always will because I've had surgery four or five times and it stuck, but, but, but it's, it's kept it in control. But the bigger thing here for me, because this was a big difference for my hips, which every single day felt, I mean, I, I woke up feeling it.

When I'd exercise, I felt it. I mean, it was something that was just constantly grinding. It felt like a grinding, and the first month it was still there after the injections. And that's not a surprise. Second month, eh? Yeah. Maybe a little improvement, but hey, maybe this didn't work. Okay. So six months down the line, I'm like, woke up and I'm, and I go through the day.

I just realized I didn't even think about my hips and I was like, oh my God. Now I'm, you know, now it's about what, you know, 10, 11 months later, no, maybe once, once in a while. If I work out really hard, maybe I'll just feel a little something, but it truly, completely, uh, solved the problem. And because of that I was like, okay.

We have a, you know, Eric's been on some of the, you know, some of the other stuff that I put out, but, you know, the heart science stuff, this is where we need, in my opinion, to hit people with, because, you know, it's not part of the mainstream. Okay. It's not part of the mainstream, and I think we need to get it there.

Okay. I, I am one anecdote, but I met like. 10 other people there with similar anecdotes. So, um, anyway, uh, I've talked enough, uh, I'm gonna go into this with you guys now. So Eric, let's start with you. Bio Accelerator. How did the company come to be?

Well, I mean, first off, thank you so much for sharing the story.

That's amazing. That's why my, my partner, chief Medical Officer, Carolyn Halpert and I have founded this company, is exactly to hear these stories. This has actually turned out to be a blessing in my life. Um, you know, Dr. Halpert here has dedicated her whole life, just like you did, you know, through me medical school and, you know, to really helping people.

And you knew that a lot, uh, earlier on in your life. My career path was much different. But it has been the blessing of my life to turn my efforts as an entrepreneur into helping other people. So I, I ended up founded in the company. We kind of joke and say, Carolyn is my, uh, my first employee, but really I was, when I founded the company, I knew I had nothing to do with a medical company.

I had no, uh, scientific aptitude. I had no medical training. So I needed a really great partner, and that's why I, uh, went out looking for Dr. Halpert, uh, my background at that moment. Was in private equity and real estate. I was, uh, I had just taken a small real estate company public. We had achieved the REIT status through single family homes.

I was marketing one of our bigger portfolios to a group that I wanted a medical tourism provider to come and take, uh, you know, to, to acquire this property. And so through those marketing efforts, looking for this medical tourism provider, uh, I found a group of stem cell scientists. And those scientists gave me somewhat of a deep dive on what was actually happening in the research laboratory.

You know, these guys were mostly researchers, but they, you know, through that research they had proven, um, that, you know, stem cell therapy for many indications is not only safe, but it's also very effective. That just got this entrepreneur light bulb that went off and I went, wow, why is this not available?

And the more and more I studied it, the more and more I got enamored, not only in just helping people, but also pioneering an industry. This was something that I thought at that moment. 10 years ago that this was going to change the way that we look at medicine, the way that medicine is prescribed, um, to be, you know, something that's more preventative and, and, uh, proactive and systemic instead of just masking symptoms and treating, um, you know, in a, in a reactive way like our typical, uh, at least US medical system is.

So that's kinda the long and short. That's what, what switched my mindset. It did take a couple years after meeting this group to really. Go out and, and start my own company. Uh, and that's when I started looking for a great partner. And that's how Dr. Halper and I got linked up. And here we are, 10 years later, celebrating a, a big milestone anniversary for a company.

There you go. So

you've described Bioxcellerator as a place where research and clinical medicine actually meet. So talk about how that works.

I think I'm gonna let Dr. Helper jump in because she's certainly the brilliance on this side, but she's, she runs the, the clinical side and the research Sure.

So, um, we are vertically integrated, so we are big three main areas.

We have the clinic side that is Bioxcellerator, and there we have different, uh, specialties, more than 14 specialties. So we have neurology, nutrition, high ecology, infertility, sports medicine, orped, neurosurgery, neurology, neuro nutrition, and much more. A total there are like. 14. Around 14, we are able to go very invasive, eh, on the procedure.

So we're not only doing IVs, we are basically injecting cells in any joint and in any space in in the body, depending on the condition. So that's the clinic side. Then we have fire stake. That is our lab and it's where we produce our own cells and we produce our products. So we have stem cell from Martin Jelly, mechy stem cells.

We have ome and exosomes from this cells. It, these are the, these are the three main products that we have. We control the whole process since the very beginning from when we collect the core from the nation with the mom. We do a very strict selection of the mom. We control all the process of quality and safety and functionality and potency and sterility, uh, up until the end of when we are preparing the therapies and the lab is just next to the clinic.

So when the therapies already, when the cells or terabytes already, uh, we send, we put them in the clinic and they, uh, are immediately applied. And this is very important because of the diabetes. So this is super important, the, the, the bio viability issue of the cells. And we also have another area that it's, uh, bioscience.

Is our research and innovation center. I have their eight epidemiologists from different backgrounds. Uh, and what we are doing there mainly is research. We have four observational studies going on. We have been collecting this data with different cohorts since. 2019. So we have very robust data collection.

All the data collection is done in the clinical care program that is very robust. That is where we do our follow up. And depending on the condition we're following up our patients. Uh, six, 12, and 24 months. Uh, and we have a lot of robust data that it's very important because this is actually real world data and real world evidence that we are building here.

Uh, we also are, um, certified by good clinical practice by in Vima. That is like. Or FDA and that allow us to do a lot of research. A majority of our conditions are treated under research or they are under observational study, or they are under K series. We have more than 20 4K series that we have been collecting a, a lot of, uh, different conditions in, in different cases, um, that it's giving us a lot of very interesting data of safety.

And of course of effectiveness, eh? So this is basically a, our vertical integration that we have. We have a quality department, eh, with a very robust quality system. We are ISO certified at the clinic. In, at the lab. And this year we started to get, um. Accreditation as a center of excellency in pain management.

So it is very related with your case, with your story of getting improvements in your, in your back and in your hip. This is the, the main cause of our patients coming to us is chronic pain and how. It makes us super happy. This is my purpose. It's really that we can help people live without pain, eh? So since this is the condition that we are more experts in pain management, it can be from, uh, joints, it could be from this, it can be from degenerative conditions.

So, you know that pain is very, um.

Broad,

broad. Thank you for the word. It's very broad and that's why we want to become the center of excellency in advanced therapy with stem cell, uh, therapy in pain management.

Let's, uh, let's drill down a little bit on the science of, of stem cells, because the, you know, that's a lot of what people in this show like to, to know about.

We talk about stem cells, um, and people have, you know, most people have vague ideas, even, you know, even the. The doctors I talked to, I mean, of course they know what stem cells are in general, but let's, let's talk about what they actually do to create a regenerative effect.

Yeah. Yeah. I think that that one is super important because actually I have many colleagues that they really don't know what a stem cell is.

So stem cells, it's, to put it in a simple way, is a cell that it's able to replicate itself, but that it's able also to, uh, turn into other type of cells. And when the body, it's being a, when the baby is an embryo, is being, um, uh, infor information, uh, everything starts from. This type of cells. So this type of cells turn into all the other tissues that we have in our body, mainly in three different layers.

So the cells that are very good for this type of therapy is the mechy stem cells. 'cause you know that there also exist in mepo stem cells. So the mechy stem cells are the ones that are from the mesodermal, and there are the ones that originate all these tissues that it's fat. Bone, uh, soft tissues. Uh, and this ones are, that's why they are very potent in regeneration and in repair when, for example, the mepo stem cell that they're getting from the bone marrow or from the blood of the umbilical cord.

Those cells are very good and are already approved by FDA and many other regulatory entities in treating ecologic conditions in in oncology conditions. So the mechy stem cells, um, depending of the source where you get them, because you can get mechy stem cells from the bone. You can get mechy stem cells from the back, or you can get mechy stem cell from the perinatal tissues.

And the perinatal tissues basically are the placenta, the amnio, or the tissue of the umbilical core. And these are the ones that we work with. That is the warton generally missing Conal stem.

And and why, why do you choose those? What, what makes them superior?

Yeah. So it's important to make a big differentiation there.

There are embryonic stem cells. They are fetal stem cells, and they are adult stem cells. All the ones that I just mentioned, perinatal tissue. They are adult stem cells, but they're coming from a very young. A tissue that is a newborn baby. So with embryonic and fetal, the embryonic stems, you have to get it from an abortion process or a, a miscarriage.

Uh, you get the cells from the embryo, also from the fetal. Uh, same. So those that has ethnic issues, uh, but also these cells are yet not completely safe because they have, uh, this. This amazing capacity, but they can also have the risk of, they can, they could turn into cancer cells. So we need more research with those cells until it's, we are comfortable to see if it's, if there's a potential for a therapy,

we meaning the industry.

The industry, we, we don't use those cells and Yeah,

we industry, yeah, we don't use those cells. We stay away from those cells. They have a risk, there are ethical issues, so we don't work with the cells. We only work with mechanical sub from the Warton jelly that is pureing natural tissues. And they are considered adult, uh, stem cells,

you know, as young as you can get adult stem cells.

So they still have, you know, a lot of the characteristics, uh, you know, of, of being able to, you know, sort of move in many different directions, but they don't have. The umbilical, uh, you know, or they don't have the fetal stem cell issues where you have potential basically to turn into cancer, for example.

Yeah. Yeah. So ones are pluripotent and the other ones are multipotent and multipotent makes them more safe because they are not going to turn into cancer cells, or they have no risk at all of the risk that you could have that, that. Uh, from the umbilical, from the fetal and from the Embry. Something else that is important is that as adult cells, uh, when you get the cells from the fat, or when you get the cells from the bone marrow, you have to put the patient to go through a procedure, liposuction aspiration that is causing inflammation, that is causing pain, and that you can get.

Two type of therapy. From those process, you can collect the fat, you can collect the bone marrow, you can do a, a, um, very easy process of centrifugation, concentration, isolation of the, those stems, and you apply immediately. But what you are applying there is actually a mixture of many other cells in not only mechy stem cells, so it's not pure of mechy stem cells.

And the number of mechy stem cells is very low. It's like a five or 10%. So when you're doing vascular fraction or bmac, uh, that you are not culturing and expanding this cells, this is actually what you are getting and this is what it's allowed in the United States. So they're getting a mixture of cells.

Of your cells, because in this case it's autologous. So this is the patient's cells that, or from the fat or from the palm marrow, they have to go through this procedure. They are the, these cells are, these tissues are affected by the age of the patient. That's super important because. My age, I, I, I'm exposed to inflammation, I'm exposed to the nutrition, I'm exposed to the environment, I'm exposed to contamination.

So, uh, are those cells really puled, uh, in the regenerative capacity? That's why they are not the ideal cells to work with.

Do, do we have data about that though? That, that there are less?

Yes. There's a lot of that.

And, and how do you measure that? How do you measure. You know, say for example, uh, adipose derived mesenchymal, uh, stem cells are, are maybe less, uh.

Potent then. Yeah. So you

measure, you measure it with, uh, ome. So you go and do the research of the proteomic. So you are, uh, actually studying what is, what are the cells releasing? So for example, the fat stem cells, uh, in the bone marrow stem cells, it's study what they have in their ome. It's study what they have in their growth factors in cytokines, uh, in, that's in, that's measure.

So there are a lot of studies that compare them and we, we can say that when you compare warton jelly with adipose and with bone marrow, warton, jelly is showing more regenerative factors being secreted, more exosomes production in more priority of of, of the role factors. Uh, not only like in quantity, but in many different role factors.

So, for example, even the, even in the, um, when we are culturing ourselves, when we started, we started, uh, with our umbilical cells. We started culturing them in Normoxia and then we. Change to hypoxia, and we measured the ome in both situations of culturing differently, and we saw that in the hypoxic conditions, the growth factors concentration in different type of growth factors and specifically.

Anti-inflammatory cytokine was increasing in a 15 or 20% compared to the normoxic even that they were being the same cells. So actually also how you culture, how is your process, is what is going to define your product. The process is the product. So that's super important. So going back to what I was trying to, my idea is that.

Uh, so when you get the fat, get the bone marrow and you do this interpretation and apply, this is what they are receiving in the space. But for example, other clinics outside the states are getting, got adipose are are getting those bone marrow in, are culturing them. So they are isolating the mechy of stem cells.

They're growing only mechy of stem cells, or they're taking mechy stem cells to 50 million to 100 million. And this one is a very pure only mechy of stem cells. But even if you have cultured them or if you have an amazing process, this cells have your age. This cells has been exposed to everything that you have been exposed.

So that's why water jelly comes very interesting. It has a lot of studies that shows the superiority of comparing with these other stem cells, and it is not only like as I'm saying, it's not only the source. Uh, it's also the process that it's super important that we control and that we have always been doing a lot of basic research in the lab to continue improving our product because whatever you put in the culture, you're gonna have a different product.

Eric, maybe there's a question for you. You know, I've been in offices, uh, or seen them online, whatever, where, you know, they advertise, uh, they actually. Say they can do Wharton's jelly stem cell injection, what are, what are they doing? Because I mean, from my understanding, that's not, it's not even legal in the, in the us right?

Yeah. So, but what is that all about?

Yeah, we can, uh, we can talk about the regulation because that, that's starting to change, but I've, if you're talking, you know, I'm going back 10 years. 10 years ago, they were doing the, the two things really that Dr. Halber was talking about, the BMAC and the, the adipose.

Now you are seeing these clinics as you're mentioning. That are saying that they're doing Wharton jelly mesenchymal stem cells and you know, the, the sad truth is they think they are. I think there's a lot of great clinicians out there that are mm-hmm. Understanding that stem cells are the future of medicine, and it's certainly something that should be prescribed in reverse of what they're typically doing.

You know, instead of having stem cells being the last. Modality that's prescribed and surgery and, and pharmaceuticals. First, it should be the reverse. So I, I am super happy for these physicians that are out there at least understanding that they should prescribe stem cells first. Um, but these great physicians, presumably they, they don't even know that they're actually.

Not giving their patients in a lot of cases, anything other than maybe some culture media growth factors. Uh, because what we've done is we've gone out and we've tested some of these, these stem cells that are being sent and shipped all across the city or across the state or across the country, and then injected by again, presumably great practitioners.

Uh, those stem cells are 0% viability from what we've tested. They're not even following actual. Regulatory pathways that, that define, uh, mesenchymal stem cells. And so what's happening is you have these laboratories that are getting on the stem cell gold rush, and they might even be great laboratories.

They might even be really trying to send a good product. They, this is again, not taking anything away from any specific laboratory. There are good ones and they're bad one, just like any other business on the planet. But these, let's say that this good laboratory is then sending their cells to a good physician.

But they, once they ship them across the city or across the state, or across the country, like I just mentioned, those cells, depending on the freezing agent that was used, which by the way, a lot of times this EMSO is, is, uh, toxic to some humans. You know, there's allergic reactions that could happen and, and, and it really needs to be handled with a lot of care and washed properly, which means that the physician then needs to have the scientific ability.

To make sure that these cells are properly, uh, you know, cleaned and activated before administration. And in almost all cases, it's not, not shipped properly. The freezing temperature isn't correct from a cryo storage, cryo preservation, um, all the way down to, you know, dry ice, down to the thawing protocol.

Those cells are ruined. The doctor doesn't know it. The patient sure doesn't know it. Until, you know, they don't get results in the future. Um, and the laboratory, you know, they're hoping for the best. I think. So. There's a big problem in our industry right now where we even have these great labs, great positions that are actually ripping patients off right now, and it's making the entire industry have a bad name.

But with what you ask about the what, how they're being able to do umbilical cord, that that's what they say. So as the fat and as the bone marrow, they get the umbilical cord. And basically, to put it very simple, they blend, they blend the tissue and they put it back. They're not expanding them, they're putting it back.

And that manipulation of the tissue, uh, is not approved by, by, by anyone, like by any regulatory entity.

Right. Um, I, I wanna dive into, uh, a little bit of the mechanism A of action, because this is also something that most, most physicians do not know. In fact, um, before I got stem cells in my hips, I went to, uh, a really good clinician, uh, locally, uh, for PRP injections.

Um, which. I took a shot at that, it, it actually didn't work for me. Now, PRP does have some pretty good data, so I'm not saying it doesn't work for a number of things, but, um, and we talked about stem cells and he didn't have a problem with trying it. But what was interesting to me is, and this is a regenerative, this is a ortho guy, um, the way he was talking about it, he made it sound as if the cells themselves, he doubted whether the cell, the cells themselves.

We're going to be able to integrate into tissue and become new tissue. Now, this is, I think, a very common misunderstanding of how the, that stem cells actually work. Um, the idea, uh, and, and perhaps you can expand on this, um, is that it's not the stem cells themselves. You alluded to it before. There is this milieu, you know, the secret tones, the things that come along.

From those stem cells that are actually triggering your own immune system to do the heavy lifting. So that is, I think, a really, really big misunderstanding. And I'll say that even back in the late nineties, uh, early two thousands, I was working, uh, I was doing some early work and in, in terms of laboratory stuff, in terms of regeneration.

Uh, in, in a neurosurgery lab. And that was kind of the assumption we had too back then is we were gonna make these stem cells actually do something themselves in the sense of integrating into tissue. But no, again, it's not those cells that were, that, that are going to create the tissue, they are going to become a signaling molecule.

Can you, uh, first of all, am I right? Uh. And, and maybe you can expand on that.

Yeah, no. So you're completely right. This, this stem cells, this cells. In the body, in vitro, they can turn into other cells, but in the body, that doesn't happen in the body. They don't turn into cartilage in the body. They don't turn into bone in the body.

They don't turn into this other cell. They are circulating a and it has been trapped. When they put a way to to trap them. They put, um, they mark them and they can see where they go into track them, and it's already proving that the cells circulate and they disappear. In six weeks, they disappear. Uh, they're clear off.

So what the cell is doing is doing, uh, a signaling. So now a proposed terminology for the mechy stencils is actually medicinal cylin cells, because what these cells are able to do is that all the growth factor in antiflammatory cytokines that they are releasing, they are activating pathways in your body.

That and, and are, are, are sending all these messages that are activating cells, that are activating passages that are going to. Push to, uh, cut inflammation to do in immunomodulation to stimulate tissue regeneration. So it's actually telling, like telling the body, eh, go this way, go that way. Uh, activate your cells, activate this mechanism to repair, to regenerate, uh, or to control inflammation as you say, by modulating the immune system.

So that's how they work.

The corollary or this follow up to that is that milieu that we talk about. Uh, part of that is, is what people have, uh, have, have come to learn as exosomes. Right? Talk about exosomes as an individual, therapy as opposed to stem cells. Like what is the difference if essentially exosomes are that milieu that we're talking about?

Why do you need the stem cells?

Yeah, that's an important question. So when we apply stem cells, let's say that we apply the stem cells in the knee, in particular application in the knee, the stem cells, they sense that microenvironment. And after sensing that microenvironment, what they start producing as a cargo, it's.

Uh, it's being influenced by that microenvironment. So the cell has the capacity to sense microenvironment to produce, uh, growth factors as specific ones for what the cells is sensing and for what is gonna be releasing through the exosomes. And that's why we. Stem cells, you have to wait a period of two to three months to start seeing results as it happened to you.

So with stem cells, we see that it takes longer, uh, and, and it go very specific on what is producing is specific for what the microenvironment of that patient. So. When we're applying exosomes, it's completely different because the exosome has already, the car defined, it has already is not producing a different car.

It's not a cell, it's not a lie. It's a vesicle that has all this ome, all these growth factors. But they are defined in determined. So when we apply them, they start working immediately and the body doesn't stop. Have to wait that the cells to says microenvironment and produce them. They start working immediately.

So that's why with exosomes we see faster results. And what we did here at By accelerator, I invented the the combination, eh, and we have amazing data that I can share with you. We were doing hypoxic cells and then we started with the combination of exosomes. Stem cells at the same time, and we start seeing that our patients were getting res uh, immediately results in pain control, eh, also after a procedure that the, the old procedure is causing more pain by itself because of the, of the inflammation of the procedure.

Add to the pain that the patient was already bringing, eh, so that pain is, it's addressed immediately. And that last, and then we see how, uh, in the two to three months, the patient continues improving and now it's because the cells are working. So the exosomes work at the beginning. Then the cells start working.

So for example, in our observational study that we have for, for knee, we have treated, uh, since July, 2020 until December, 2024. This was one of the cohorts if, uh, 421 patients. And we had 98 patients with exosomes in cells in 14. 421 with only sales because we had been doing only sales for longer and we started doing the combination only.

In the last two years. And when we compare, uh, I can tell you that in the, the patient in the knee, that is, we followed the Walmart, we followed the bas, uh, in only cells. The improvement was, uh, 71%. But when we were doing the combination of stem cells and exosomes, we were seeing an improvement of about 75%.

Was there an exosome only group?

No, we, we don't have that core yet because the majority of our patients. They want stem cells and now they want stem cells with exosomes. But for example, we, since we were working first with normoxic cells, uh, we have the cohort of we can compare normoxic cells with hypoxic cells.

And in this study of the knee, the normoxic cells were improving of 40%. So from a 40 with Normoxic to a 61 to hypoxic to a 75 with the combination of hypoxic stem cells with exosomes, and that's pretty amazing. We have observational studies with shoulder or shoulder conditions, elbow A and the degenerative, this disease, and it's very consistent that when we have the combination, there's an increase of improvement between a 10 and a 15%.

These are the kind of things, this is why we've kind of, you know, affectionately been given the term by other clinics and clinicians, the, you know, the, the global standard in regenerative medicine. And, and we're, we're trying to set the standard, but we're doing it through the hard work and research of actually trying to prove the exact results and the exact increases at what point, at what lever point.

So, uh, we're very happy with the results, but we wanna keep making it better.

The reason I was asking about the, uh, potential exosome only arm is that exosomes from a regulatory standpoint, um, it, it seems to be a much easier lift in the United States. And, um, can you talk a little bit about that? Uh, either, Eric, maybe this is for you just in terms of.

The current stand, you already see people, um, providing quote unquote exosomes. I don't know where they're getting them from. I even saw, uh, someplace that was doing plant exosomes, and I'm like, what, what are you, I don't even understand. But, um, but maybe you can talk a little bit about, you know, the regulatory, uh, framework for exosomes in the United States right now.

Yeah, we're very happy to see that there's a few states in the union that are going against the FDA in their regulatory pathway, or at least their, their understanding of. How to apply stem cells safely. And we think that that's gonna transition much quicker with exosomes. But to answer your exact question, exosomes is still a very much in a gray area.

Uh, very much like peptides, very much like stem cells. Um, so we are seeing it more mass adopted because it does not have the logistical shipping issues. I mentioned earlier where you have this great lab that then ships their great product and then that product dies and is worth nothing. Um, but they're selling it anyways.

At least with exosomes, you can ship a, a good product and have it still be good at the point of application. So we're seeing it a little bit more widely adopted, but what I'll, what I'll say is that to Dr. Halbert's, um, you know, one, something that she mentioned earlier is that the process. Is the product and that that goes along, that coincides with exosomes just as much as it does stem cells.

We have developed this, this product that is together, our cells and our exosomes are made together to be together, um, very specifically. But, you know, even if they're separated, they are each individually good. And so again, focusing on the exosomes, this incredible process that we put together, which makes an ultra purified exosome, which is not what we're seeing in the marketplace.

Mostly we're seeing a very low level exosome. The good news is that they're being shipped and they're, they're not dying like stem cells. So there's a better, uh, consistency of, of patients seeing some results, but from a regulatory framework, the truth is, is it's still a wild, wild west, very gray area in the United States.

What we see with, uh, RFK and his administration, um, in health and human services and FDA, is that they're just not enforcing. As at this point, but I, I think that that's probably gonna change, you know, he's, he's not gonna be in office forever.

Yeah. That's the, that's the challenge, right? Um, that, that is the challenge is like, you know, they're not enforcing, uh, but they're not necessarily making, um, uh, some changes that regenerative C clinics could rely on and say, well, this is definitely something I can do.

In five years from now, right?

No, this is the whole reason that our company was forced offshore. I'm in Scottsdale, Arizona right now where our corporate office is. You know, we're an American company, but we wanted to do it legally. We wanted to do it the right way, and we found out very quickly that that's not here in the United States, and that's why you see the best clinics.

Offshore at this point, hopefully the, the US will turn around. We need to bring this technology to as many people as possible.

What are you seeing on that front? I mean, I actually, you know, I know Eric, I know you've actually, you know, met with RFK, uh, junior. Um, I mean, are you, are you hopeful or do you feel like this is still something that we're gonna need to wait a, a, a lot longer?

It's, it's a little bit of both. Um, you know, I'm very happy to see that we are making some progress. And again, it's, it's state by state. So right now, Florida and Utah, and there's some other states that have put out some regulation that say, no, we are gonna allow our, our, uh, constituents, our, the, the public to have access to this therapy for specific reasons like wound care and pain management.

Some orthopedic issues. Um, you know, specifically talking about Florida. So we have these states and the union that are going completely against the FDA, that still runs a big risk. But if you look at it, if you look at the history of our country, allowing things like cannabis. State by state and going against the, the FDA and against the federal government, um, and their regulatory framework for, for cannabis.

Uh, you know, even being a Schedule one drug at one point, um, you know, we know it, it can happen and we know that that is the precipice of opening up the entire country to having access to this. But you know, if you just look at cannabis, not every state even allows cannabis still. I think there's only 20 states in immune after 20 years.

So. It's still gonna be a long pathway, but we we're trending in the right direction.

I, I wanna compliment that I think that regulation is super important because what we are seeing, it's for example, that any companies are selling exosomes as exosomes and they're not really exosomes is a condition in media or is ome that this is three products, completely different Saum.

Exosomes and Condition Media. They are good, but they are completely different, uh, in the, and the production of exosomes has a very specific, uh, not easy process of ultra certification via filtration that these companies are cutting. And they're saying that this secretive or combination of not only exosome by many other proteins, they're saying it as.

If they are exosomes, and that's what I think that regulation is super important because there have to be someone that to that. That makes the companies really, uh, have a very good product and that they really sell what they're saying they are selling. And what worries me a lot is that many of my colleagues, our colleagues, they don't even know what they are applying.

And you can put whatever in paper, in their certificates, they can say whatever. You can put whatever in paper. But it's, is it really that what is in the inside, the vi.

Yeah. One thing I wanna kind of go back to again, just, uh, so people have a sense of this too. We've talked about in my, my, in the context of what my story is, it's been, uh, my, you know, my hips and my back and, and stuff like that.

But there's, there's a, a big broad, uh, there's a broad application of a, a number of other things that you're treating. Can you. Can you talk a little bit about some of the things you might not expect, uh, some of the benefits that, that you have seen?

Well, I always like to talk about, um, autism. We have, uh, we have treated, uh, like five or six kids.

And with three of them having amazing improvements, little kids that they were not doing s in the spectrum, they were very severe. They were not doing eye contact. They were no communication at all, no words. And then it's, for us is it's, were very happy when the moms send us videos and we were doing the follow up with the scores and the skills and everything that we do.

An objective measure when we see these kids, uh. Talking. Interacting, having a conversation, making eye contact. That's a big change in that family dynamic. And in that, the kiddo,

why would it benefit an, uh, autism?

So it's not in all the cases of autism, it has to be a correlation that, uh, there's some neuro inflammation going on and, and when we are applying our particle, it's.

It's, it's aggressive. It's very different from all the others because we go inco and iv. We do both. Uh, and I see. I think that's why we see the results that we see and how this is working is that it's actually modulating the inflammation in the nervous system. Uh, and that's how it works. So it has to be some narrow inflammation related, eh, so that we can expect, uh, to see improvements.

So it's not that this therapy is gonna be good for all the spectrum kids, it's has to be very selected, eh, the specific cases that you have a suspicious of network inflammation going on. Other cases, for example, spinal cord, spinal cord injury patients, they don't have any other option and they're coming to us if they come very soon.

And this is something super important to educate our colleagues, is that if they come very soon after the injury, they can expect better results. So we have several cases that we have been able to treat in the first six months after injury, and they have recovered a lot of motor and sensitive function and for example, uh, patients coming quad and being strapped to the chair, hands strap because no control at all.

Then now being able to have more independency in their life because we're able to move their hands and to have the. To be able to grab so that they can feed themselves or that they can move their chair by themselves so they have more dependency. Those cases are, they make me cry. They made me cry at the stations.

Yeah. Yeah. I

actually met one of the, met one of those types of people when I was there.

Maybe you met Dustin, maybe. He was

a, was he he was like an MMA fighter or something? Ah,

yes.

Oh yeah. He's He's running again. He's running. Yeah,

he he's walking.

Yeah.

And it's because he had very high injury cervical injury, but he was uncomplete and he came very fast.

So when he came to us, he was squat and now he is walking and that's like incredible, amazing.

Um. What about, there is some like, uh, you would think autoimmune disease would be another one because if you're, you know, essentially a lot of the effect here is, uh, immunologic benefit.

Yeah. So the conditions that we're seeing very good results is rheumatoid arthritis, multiple sc.

Ankylosis Spondylitis. Ankylotic. An ankylosis, spondylitis, I dunno how you say that in English.

Yeah. Spondylitis. Ankylos. Yeah. Yeah, I know what you're talking about. Sure. Okay.

Sorry. But I, I get that word is difficult for me in English. Uh, and we also see very good results in Crohn disease. So all of them are autoimmune conditions.

Where we are seeing, um, especially in ms in, is patients that, uh, that have recovered even their dys, that their capacit, their capacity of talking clearly, that they have recovered in their, in, in their. Ability to swallow that they have. So we have a case that it's beautiful because she sent us this email, this video, how she was talking before, how she's talking often super clear.

You can understand her, eh? And she said like, my disorder completely changed. Uh, so in multiple sclerosis, eh, important, important, um, results.

Fascinating stuff. Uh, Eric, anything, uh, anything else? Uh, you want a little message to the doctors listening out there?

Yeah. I guess to the docs, you know, one of the things that we like to do is we like to educate all of our colleagues and all of our people that are interested in the field so that, you know, whether you're doing business with us or sending patients to us, that that's not the point.

The point is that you're doing it the right way. You, you know what the best practices are. So we're happy to do that. Um, you know, we have a healthcare provider program where we really appreciate, um, anybody's interest in, in advancing this field so that we can all help as many people together. And we're at Bioxcellerator.com and you can find us on any social channel and, you know, look us up that way.

Fantastic.

Alright guys. Uh, thanks so much for joining me on the show. Uh, it's always a, a pleasure and, uh, you know, I would love to have you on again, as, as this sort of story, this story

unfolds over time. Thank you very much. Thank you. Thank you. We always appreciate the opportunity. Yeah. And I'm so happy to hear that you're, yeah.

You're, uh, feeling a lot better the first time. Easy. Yeah. Thank you.

Thanks for listening. A quick reminder that while I am in fact a surgeon, nothing I say should be construed as medical advice. Now, make sure to include your physician in any medical decisions you make, and also, if you're enjoying the show, please make sure to show your support with the like, share, or subscribe.